KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

por Serna-Blasco, R., Sánchez-Herrero, E., Sanz-Moreno, S., Rodriguez-Festa, A., García-Veros, E., Casarrubios, M., Sierra-Rodero, B., Laza-Briviesca, R., Cruz-Bermúdez, A., Mielgo-Rubio, X., Sánchez-Hernández, A., Uribelarrea, E.A., Calvo, V., Romero, A., Provencio, M.
Publicado 2021